Phase 2
N=114
NSAID Effects on Clinical and Imaging Breast Biomarkers
Inflammation · Cancer · Pain · Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT01761877 ↗Enrolled (actual)
114
Serious AEs
4.0%
Results posted
Feb 2023
Primary outcome: Primary: Change in Breast Density Measured as Fat to Water Ratio by Magnetic Resonance Imaging — -9.8; -3.6 percent change in breast density — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Sulindac (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- Female
- Sponsor
- Stony Brook University
- Primary completion
- Feb 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Breast Density Measured as Fat to Water Ratio by Magnetic Resonance Imaging |
-9.8; -3.6 | <0.05 sig |
| SECONDARY Muscle and Joint Pain and Stiffness |
-5.85; -0.25 | <0.05 sig |
Summary
This study has two purposes. One is to determine if daily sulindac decreases breast density; a risk factor for breast cancer development. The second is to determine whether sulindac reduces pain and stiffness associated with regular use of aromatase inhibitors given for the treatment of breast cancer.
Eligibility Criteria
Inclusion Criteria
- Eligibility criteria will include: Postmenopausal women with of first incidence of early stage (stages 0 - III) hormone receptor positive breast cancer stabilized on anastrozole therapy for at least 3 months
- Patients must have started on anastrozole and plan to continue on anastrozole therapy for a minimum of 12 months
- Patients must have an unaffected, non-irradiated contralateral breast with a baseline breast density score of > 25% as measured by standard digital mammography (BIRADs score > 2) or magnetic resonance imaging (MRI) performed within 12 months of randomization to the study
- A willingness to follow the study protocol, as indicated by provision of informed consent to participate
- A willingness to avoid taking NSAIDs outside of the trial (rare NSAID use for musculoskeletal symptoms excepted)
- Normal renal function as determined by a serum creatinine 75 years
- History of cardiovascular disease including prior myocardial infarction, angina, stroke, or transient ischemic attack (TIA)
- Diabetes requiring drug therapy
- Current smoker
- History of Uncontrolled hypertension
- Blood pressure > 140/90 at baseline by home monitoring
- History of GI ulcers, chronic GERD, or GI bleeding in the past 5 years
- History of a bleeding diathesis or current anticoagulant therapy
- Daily therapy with H2 blockers or protein pump inhibitors
- History of claustrophobia
- Have electrically, magnetically, or mechanically activated implants including cardiac pacemaker, cochlear implants, magnetic surgical clips or prostheses.
Data sourced from ClinicalTrials.gov (NCT01761877). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.